Tonix will test its mon­key­pox vac­cine in Kenya next year, and no eyes on ac­cel­er­at­ed path at FDA

As mon­key­pox spreads across dozens of coun­tries, one of the few biotechs pub­licly work­ing on a new vac­cine for the virus is gear­ing up to en­ter the clin­ic in the first half of next year.

The study of Tonix Phar­ma­ceu­ti­cals’ live virus vac­cine will oc­cur at Kenya Med­ical Re­search In­sti­tute, or KEM­RI, in the East African coun­try, the part­ners said Thurs­day. While Kenya has no re­port­ed cas­es of the virus that leads to painful le­sions, the coun­try is close to the De­mo­c­ra­t­ic Re­pub­lic of the Con­go, which had 163 cas­es as of Ju­ly 27, ac­cord­ing to a CDC track­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER